Comparative effectiveness of immunotherapy versus lenvatinib in advanced hepatocellular carcinoma: A real-world analysis using target trial emulation
In this real-world analysis, immunotherapy was associated with improved OS compared to lenvatinib in advanced HCC, with consistent benefit across most subgroups. These findings support the use of immunotherapy as a first-line treatment for advanced HCC.
Authors
- Walid S. Ayoub (ORCID: https://orcid.org/0000-0002-9123-5918)
- Amit Singal (ORCID: https://orcid.org/0000-0002-2882-0436)
- Alexander Kuo (ORCID: https://orcid.org/0000-0002-9106-8865)
- Hirsh D. Trivedi (ORCID: https://orcid.org/0000-0002-8328-9211)
- Ju Dong Yang (ORCID: https://orcid.org/0000-0001-7834-9825)
- Yee Hui Yeo (ORCID: https://orcid.org/0000-0002-2703-5954)
- Wee Han Ng
- Neehar D. Parikh (ORCID: https://orcid.org/0000-0002-5874-9933)
- Nicole E. Rich (ORCID: https://orcid.org/0000-0003-2740-8818)
- Joseph Ahn (ORCID: https://orcid.org/0000-0001-6994-2870)
- Kevin Sheng‐Kai (ORCID: https://orcid.org/0000-0002-9394-4144)
- Ghassan K. Abou‐Alfa (ORCID: https://orcid.org/0000-0002-1522-8054)
- Hyun‐Seok Kim (ORCID: https://orcid.org/0000-0003-1127-5766)
- Yun Wang (ORCID: https://orcid.org/0000-0001-7146-8290)
Institutions
- Boston University (US)
- Cedars-Sinai Medical Center (US)
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- Harvard University (US)
- Cornell University (US)
- University of Michigan (US)
- WinnMed (US)
- University of Bristol (GB)
- Southwestern Medical Center (US)
- Mayo Clinic in Arizona (US)
- Center for Global Health (US)
- Southwestern Medical Center (US)
- University of Pennsylvania (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Hepatology
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1097/hep.0000000000001328
- Citations
- 11
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 14.54